Malvern-based Annovis Bio, a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders, recently filed three patents for innovative combination therapies using buntanetap, its lead compound.
Buntanetap inhibits the production of neurotoxic proteins. Studies have shown it can improve cognition in early Alzheimer’s disease patients and halt cognitive decline in Parkinson’s disease patients.
When combined with a GLP-1 agonist or PDE5 inhibitors, buntanetap has improved cognitive function in Alzheimer’s mouse models to levels beyond those observed in healthy controls.
The company’s patent filings involve buntanetap combined with Trulicity (dulaglutide) or Viagra (sildenafil), and a combination of all three.
“Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” Dr. Maria Maccecchini, Annovis Bio founder, president, and CEO, said. “The combination of buntanetap with Trulicity and Viagra not only has the potential to restore cognition to healthy levels, but also to improve it beyond normal, offering new hope in the fight against dementia. Since buntanetap has completed Phase 3 studies as a standalone treatment, and both Trulicity and Viagra are FDA-approved, these combinations are well-positioned for Phase 3 human trials.”
By filing the patents, Annovis hopes to expand its pipeline and advance the company’s mission.